Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

After increases over the past three years, the five-year relative survival rate for pancreatic cancer remains flat at 13%, ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President ...

在这项最新研究中，研究团队发现了一种小分子——CT-1，它是隐丹参酮（CTS）的衍生物，能够有效抑制三阴性乳腺癌（TNBC）的生长，同时显著降低肿瘤组织中 N2 型肿瘤相关中性粒细胞（N2 型 TAN）的比例。

Brian DeSchuytner, the Senior Vice President, Chief Operating Officer, and Chief Financial Officer of Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently reported a transaction involving the company's ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...

Diebold Nixdorf , a world leader in transforming the way people bank and shop, will release fourth quarter and full-year 2024 financial results on Wednesday, Feb. 12, before trading begins on the New ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...

【导读】癌症免疫疗法的疗效依赖于足够数量的功能性免疫细胞。三阴性乳腺癌缺乏足够的免疫细胞浸润，因此，需要辅助治疗来增强抗肿瘤免疫力。然而，由于担心诱发全身免疫毒性，疗效的改善并不令人满意。在这项研究中，团队创建了一种由多肽-药物双亲化合物形成的阿贝西 ...

Avacta Therapeutics announced promising results from its ongoing phase 1a trial of AVA6000 on Thursday, demonstrating ...